CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a novel therapeutic approach for Alzheimer's disease by utilizing the body's cellular waste disposal system to selectively degrade amyloid-beta peptides. By targeting specific cytotoxic forms of these peptides, the research seeks to mitigate neuroinflammation and neurodegeneration associate…
The amyloid-beta (A) protein arises from the sequential proteolytic cleavage of A precursor protein (APP).
The accumulation of A oligomers has been regarded as the causal factor of Alzheimers disease (AD).
Basal metabolic production of the A peptide is typical in healthy people, and its production rate is normally lower than its rate of clearance.
In AD, the uncontrolled accumulation of toxic forms of A stemming from problems in its clearance and degradation results in memory loss, chronic neuro…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Mannheim
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
